• Delic is a leader in new medicines and treatments that offers education, research, high-quality products, and treatment options
• The company is on a mission to help heal the mental health pandemic, which has been triggered and worsened by the COVID-19 disease
• Delic operates the largest, most profitable chain of wellness clinics providing ketamine treatments in the United States
• With 13 clinics already in operation, Delic is eyeing expansion as it seeks to ensure 60-70% of Americans are within a 45-minute drive to its clinics

The latest data from the World Health Organization (“WHO”) shows that the COVID-19 pandemic has triggered a 25% increase in the number of cases of anxiety and depression globally. Caused by multiple exacerbating factors, including loneliness, suffering and death, fear of infection, financial worries, and grief, this increased prevalence has also coincided with the substantial disruption in mental health services, creating a gaping hole in the care of people leaving with these conditions (https://ibn.fm/Tzpcj).

Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leader in new medicines and treatments for a modern world, has stepped up its efforts as it looks to fill the gaps exposed by COVID-19’s battering of the health sector. “Our mission is to heal the planet. We want to help heal the mental health pandemic. I don’t think we could have come about at a better time. I think it’s necessary; I wish it weren’t so necessary, but it is, and so, when people need that help, we are here to provide it,” Delic Co-founder and CEO, Matt Stang, said in a January interview (https://ibn.fm/Ycnhe).

To fulfill this mission, Delic offers education, through an impressive, assorted portfolio of media offerings, including a wellness event, digital lifestyle magazine, and podcast; research through Delic Labs, a federally-licensed cannabis and psilocybin research lab; and, most importantly, high-quality products and treatment options through wellness clinics operating under the Ketamine Wellness Centers brand.

The company currently operates 13 wellness clinics across nine states, making it the owner of the largest, most profitable chain of wellness clinics in the United States. Looking ahead, Delic plans to maintain this lead with plans to open more clinics in multiple other locations. Ultimately, according to Stang, the company’s long-term vision for this expansion drive is to have 60-70% of the American population within a 45-minute drive to the clinics. The expansion is also strategic in other ways.

During the interview, Stang estimated that some psychedelic substances such as MDMA (ecstasy) and psilocybin could receive “some form of approval” within the next one to two years, with other compounds slated for possible legal availability in the subsequent years. Accordingly, Delic is positioning its clinics to be the go-to wellness centers for patients once the nascent psychedelic drugs are finally available.

“[Once the psychedelic drugs have received some form of FDA approval] Delic will be the place you can go – you’ll have a clinic in your backyard that you go to for psychedelic medicine treatment, just like any other type of pharmaceutical,” Stang explained. He further noted that the clinics will offer psychedelic medicine treatment on an in-person basis, where qualified professionals will sit with patients and walk them through the process, offering them the efficacy they seek and, as a result, helping them change their minds and lives.

Through the Ketamine Wellness Centers, Delic is providing a scalable, trusted, and accessible network of psychedelic clinics with a repeatable, non-habit forming, and effective treatment process. The clinics, coupled with its research and development division, put the company at the center of the burgeoning psychedelics and mental health treatment industries.

According to an Open Minds Market Intelligence Report, the spending on mental health treatment and services grew 52.1% between 2009 and 2019, reaching $225 billion (https://ibn.fm/dZpEf). Separately, the global psychedelic drugs market is expected to grow robustly at a CAGR of 14.5% between 2021 and 2026, from $3.21 billion to $6.33 billion (https://ibn.fm/uC6nJ).

For more information, visit the company’s website at www.DelicCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]